Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting ...

Q4 2024 Management View CEO Mark Newcomer highlighted that Paysign achieved exceptional growth in its patient affordability business in 2024, with annual revenue increasing by 212% to $12.7 million.

CFO Lisa Roger reported Q4 2024 revenue of $2.8 million, detailing the growth was driven by expanded bottle production capacity and increased sales volumes. Full-year revenue reached $10.7 million, ...